- What: Pfizer is partnering with PATH and others to support StartHealth, an investment programme that assists entrepreneurs to develop technology solutions aimed at improving access to healthcare in India.
- Context: The programme was launched in February 2015.
- Objective: It coordinates technical support, mentoring, grant funding and capital investment to support the local development of affordable, effective and sustainable health products and services for the poor.
- Details: Areas of focus include: low-cost diagnostic devices, therapeutic/monitoring devices and technology-enabled health service delivery.
Pfizer is collaborating with Unitus Seed Fund, PATH and other partners to support StartHealth, an investment programme supporting health technology start-ups in India. The programme, launched in February 2015, coordinates technical support, mentoring, grant funding and capital investment to support local entrepreneurs to create affordable, effective and sustainable health products and services for the poor. Successful applicants can also access, where relevant, hospitals and other health facilities for pilots and market testing. Areas of interest for grants include (but are not limited to): low-cost diagnostic devices; low-cost therapeutic/monitoring devices; and technology-enabled service delivery in sectors such as maternity, chronic disease management and cancer care.
Initiatives already supported include: a mobile application linking patients who may have experienced a heart attack with expert cardiologists, helping to address the low number of cardiologists in India; and a low-cost, portable breast screening device, helping to address the often-late stage at which breast cancer is diagnosed in India, which negatively impacts survival rates.
Pfizer’s partnership with locally-based seed-stage investor Unitus Seed Fund in India represents a unique means of supporting – both financially and technically – innovative approaches to speed up the development of technology-based solutions to local health access challenges.